Ftse Mib
32.665,21
-2,81%
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.234,96
-0,61%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Pasithea Therapeutics Corporation (KTTA) Pasithea Therapeutics Corporation (KTTA) Notizie

KTTA

Pasithea Therapeutics (KTTA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KTTA
DataOraFonteTitoloSimboloCompagnia
13/06/202412:59GlobeNewswire Inc.Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialNASDAQ:KTTAPasithea Therapeutics Corporation
28/05/202412:59GlobeNewswire Inc.Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
29/04/202413:59GlobeNewswire Inc.Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
24/04/202413:59GlobeNewswire Inc.Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersNASDAQ:KTTAPasithea Therapeutics Corporation
02/03/202403:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
13/02/202413:59GlobeNewswire Inc.Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004NASDAQ:KTTAPasithea Therapeutics Corporation
18/01/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
08/01/202413:59GlobeNewswire Inc.Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionNASDAQ:KTTAPasithea Therapeutics Corporation
02/01/202414:35GlobeNewswire Inc.Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsNASDAQ:KTTAPasithea Therapeutics Corporation
28/12/202323:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KTTAPasithea Therapeutics Corporation
28/12/202323:00GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023NASDAQ:KTTAPasithea Therapeutics Corporation
19/12/202323:19GlobeNewswire Inc.Pasithea Therapeutics Announces Results from 2023 Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
11/12/202314:01GlobeNewswire Inc.Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNASDAQ:KTTAPasithea Therapeutics Corporation
29/11/202322:27GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNASDAQ:KTTAPasithea Therapeutics Corporation
29/11/202313:59GlobeNewswire Inc.Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNASDAQ:KTTAPasithea Therapeutics Corporation
13/11/202322:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KTTAPasithea Therapeutics Corporation
09/11/202313:59GlobeNewswire Inc.Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSNASDAQ:KTTAPasithea Therapeutics Corporation
26/10/202323:01Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTTAPasithea Therapeutics Corporation
26/10/202323:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KTTAPasithea Therapeutics Corporation
16/10/202323:18Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:KTTAPasithea Therapeutics Corporation
14/09/202315:15Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:KTTAPasithea Therapeutics Corporation
14/09/202314:30GlobeNewswire Inc.Pasithea Therapeutics Corp. Announces Final Results of Tender OfferNASDAQ:KTTAPasithea Therapeutics Corporation
07/09/202322:14GlobeNewswire Inc.Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:KTTAPasithea Therapeutics Corporation
09/08/202315:08Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:KTTAPasithea Therapeutics Corporation
01/08/202313:59GlobeNewswire Inc.Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviNASDAQ:KTTAPasithea Therapeutics Corporation
20/07/202315:03Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:KTTAPasithea Therapeutics Corporation
20/07/202314:43GlobeNewswire Inc.Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in CashNASDAQ:KTTAPasithea Therapeutics Corporation
20/07/202314:40GlobeNewswire Inc.Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.NASDAQ:KTTAPasithea Therapeutics Corporation
03/07/202323:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
30/06/202315:28GlobeNewswire Inc.Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of DirectorsNASDAQ:KTTAPasithea Therapeutics Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KTTA

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
BPE
Bper Banca
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
BAMI
Banco BPM
BIT
RACE
Ferrari NV
BIT
SPM
Saipem
BIT
G
Generali
BIT
NEXI
Nexi S.p.A
BIT
TIT
Telecom Italia
BIT
PST
Poste Italiane S.p.a
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network